. 2025 Aug 3;15(8):e097134.

doi: 10.1136/bmjopen-2024-097134.

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings

Banafshe Hosseini^{1

2

3}, Amanda Condon⁴, Bruno R da Costa^{5

6}, Peter Daley^{7

8}, Michelle Greiver^{2

9}, Peter Jüni^{5

10}, Todd C Lee¹¹, Kerry McBrien^{12

13}, Emily G McDonald^{14

15}, Srinivas Murthy¹⁶, Peter Selby^{2

3

17}, Melissa Andrew¹⁸, Kris Aubrey-Bassler¹⁹, David Barber²⁰, Brendan Barrett²¹, Christopher C Butler²², Noah Crampton², Simone Dahrouge²³, Ali Damji², Robert Fowler⁶, Stephanie Garies²⁴, Catherine Hudon²⁵, Jennifer Hulme², Jennifer Isenor^{26

27}, David J A Jenkins^{28

29}, Rosemarie Lall², Annie LeBlanc³⁰, Christine Leong³¹, Paul Little³², Aisha Lofters^{33

33

34

35}, Sarvesh Logsetty³⁶, Sylvain Lother^{37

38}, Marie-Thérèse Lussier^{39

40}, Laura Maclaren⁴¹, Dee Mangin⁴², Emily Gard Marshall⁴³, John C Marshall⁴⁴, Rita McCracken^{45

46}, Rahim Moineddin^{2

10}, Brianna Orava⁴⁷, Jean-Sébastien Paquette^{48

49

50}, Jay Jae Hee Park⁵¹, Nav Persaud^{2

34

52}, Valeria E Rac^{6

53}, Vivian R Ramsden⁵⁴, Jennifer Rayner⁵⁵, Diana C Sanchez-Ramirez⁵⁶, Lynora Saxinger⁵⁷, Haolun Shi⁵⁸, Alexander Singer^{4

59}, Rae Spiwak^{60

61}, Anita Srivastava², Abhimanyu Sud^{2

62}, Jean-Eric Tarride⁵¹, Deanna Telner^{2

63}, Ross E G Upshur^{2

3

64}, Sakina Walji², Rachel Walsh^{2

65

66}, Machelle Wilchesky^{67

68}, Sabrina T Wong⁶⁹, Brianne Wood^{70

71}, Ryan Zarychanski⁷², Barb Zelek⁷¹, Yoav Keynan^{73

74}, Jolanta Piszczek⁷⁵, Daniel Warshafsky^{76

77}, Andrew David Pinto^{78

2

3

34}

Affiliations

¹ Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada.
² Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
⁴ Department of Family Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁵ Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
⁶ Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
⁷ Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
⁸ Eastern Regional Health Authority, St. John's, Newfoundland and Labrador, Canada.
⁹ Department of Family and Community Medicine, North York General Hospital, Toronto, Ontario, Canada.
¹⁰ Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
¹¹ Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
¹² Department of Family Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
¹³ Department Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
¹⁴ Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Quebec, Canada.
¹⁵ Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Quebec, Canada.
¹⁶ Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁷ Addiction Programs, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
¹⁸ Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Halifax, Nova Scotia, Canada.
¹⁹ Primary Healthcare Research Unit, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
²⁰ Department of Family Medicine, Queen's University, Kingston, Ontario, Canada.
²¹ Medicine Nephrology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
²² Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK.
²³ Elisabeth Bruyere Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
²⁴ Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
²⁵ Université de Sherbrooke, Sherbrooke, Quebec, Canada.
²⁶ College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada.
²⁷ Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada.
²⁸ Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
²⁹ Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada.
³⁰ VITAM Research Center on Sustainable Health, Sherbrooke, Quebec, Canada.
³¹ College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
³² Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.
³³ Department of Family and Community Medicine, Women's College Hospital, Toronto, Ontario, Canada.
³⁴ Department of Family and Community Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
³⁵ Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
³⁶ Departments of Surgery and Psychiatry, University of Manitoba, Winnipeg, Manitoba, Canada.
³⁷ Department of Internal Medicine, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada.
³⁸ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
³⁹ CHUM Research Center, Université de Montréal's affiliated hospital research center, Montréal, Québec, Canada.
⁴⁰ Département de médecine de famille et de médecine d'urgence, Université de Montréal, Montréal, Québec, Canada.
⁴¹ Department of Family Medicine, McGill University Faculty of Medicine and Health Sciences, Montreal, Quebec, Canada.
⁴² Public Health and General Practice, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand.
⁴³ Family Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
⁴⁴ Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
⁴⁵ Family Medicine, Providence Health Care, Vancouver, British Columbia, Canada.
⁴⁶ Family Practice, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
⁴⁷ Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
⁴⁸ VITAM - Research Centre on Sustainable Health, Sherbrooke, Québec, Canada.
⁴⁹ Département de médecine de famille et de médecine d'urgence, Université Laval, Quebec City, Québec, Canada.
⁵⁰ Laboratoire ARIMED, Saint-Charles-Borromée, Québec, Canada.
⁵¹ Department of Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
⁵² MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
⁵³ Program for Health System and Technology Evaluation, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
⁵⁴ Department of Family Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
⁵⁵ Alliance for Healthier Communities, Toronto, Ontario, Canada.
⁵⁶ College of Rehabilitation Sciences, Department of Respiratory Therapy, University of Manitoba, Winnipeg, Manitoba, Canada.
⁵⁷ Department of Medicine, Division of Infectious Diseases, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada.
⁵⁸ Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.
⁵⁹ Manitoba Primary Care Research Network, Winnipeg, Manitoba, Canada.
⁶⁰ Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁶¹ Manitoba Centre for Health Policy, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁶² Research Institute, Humber River Health, Toronto, Ontario, Canada.
⁶³ South East Toronto Family Health Team, Toronto, Ontario, Canada.
⁶⁴ Joint Centre for Bioethics, University of Toronto, Toronto, Ontario, Canada.
⁶⁵ Evaluative Clinical Sciences Platform, Integrated Community Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁶⁶ Sunnybrook Academic Family Health Team, Toronto, Ontario, Canada.
⁶⁷ Departments of Medicine and of Family Medicine, McGill University, Montreal, Quebec, Canada.
⁶⁸ Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
⁶⁹ Centre for Health Services and Policy Research, University of British Columbia, Vancouver, British Columbia, Canada.
⁷⁰ Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario, Canada.
⁷¹ Dr. Gilles Arcand Centre for Health Equity, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.
⁷² Sections of Critical Care and Hematology/Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.
⁷³ Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
⁷⁴ Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁷⁵ Faculty of Pharmacy, The University of British Columbia, Vancouver, British Columbia, Canada.
⁷⁶ School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
⁷⁷ Ontario Ministry of Health, Toronto, Ontario, Canada.
⁷⁸ Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada andrew.pinto@utoronto.ca.

PMID: 40754325
PMCID: PMC12320028
DOI: 10.1136/bmjopen-2024-097134

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings

Banafshe Hosseini et al. BMJ Open. 2025.

. 2025 Aug 3;15(8):e097134.

doi: 10.1136/bmjopen-2024-097134.

Authors

Affiliations

¹ Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada.
² Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
³ Division of Clinical Public Health, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
⁴ Department of Family Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁵ Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
⁶ Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
⁷ Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
⁸ Eastern Regional Health Authority, St. John's, Newfoundland and Labrador, Canada.
⁹ Department of Family and Community Medicine, North York General Hospital, Toronto, Ontario, Canada.
¹⁰ Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
¹¹ Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
¹² Department of Family Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.
¹³ Department Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
¹⁴ Division of Experimental Medicine, Department of Medicine, McGill University, Montréal, Quebec, Canada.
¹⁵ Division of General Internal Medicine, Department of Medicine, McGill University, Montréal, Quebec, Canada.
¹⁶ Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
¹⁷ Addiction Programs, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
¹⁸ Department of Medicine (Division of Geriatric Medicine), Dalhousie University, Halifax, Nova Scotia, Canada.
¹⁹ Primary Healthcare Research Unit, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
²⁰ Department of Family Medicine, Queen's University, Kingston, Ontario, Canada.
²¹ Medicine Nephrology, Memorial University of Newfoundland, St. John's, Newfoundland and Labrador, Canada.
²² Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK.
²³ Elisabeth Bruyere Research Institute, University of Ottawa, Ottawa, Ontario, Canada.
²⁴ Department of Family Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
²⁵ Université de Sherbrooke, Sherbrooke, Quebec, Canada.
²⁶ College of Pharmacy, Dalhousie University, Halifax, Nova Scotia, Canada.
²⁷ Canadian Center for Vaccinology, Dalhousie University, Halifax, Nova Scotia, Canada.
²⁸ Department of Nutritional Sciences, University of Toronto, Toronto, Ontario, Canada.
²⁹ Risk Factor Modification Centre, St. Michael's Hospital, Toronto, Ontario, Canada.
³⁰ VITAM Research Center on Sustainable Health, Sherbrooke, Quebec, Canada.
³¹ College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.
³² Primary Care Research Centre, School of Primary Care, Population Sciences and Medical Education, Faculty of Medicine, University of Southampton, Southampton, UK.
³³ Department of Family and Community Medicine, Women's College Hospital, Toronto, Ontario, Canada.
³⁴ Department of Family and Community Medicine, St. Michael's Hospital, Toronto, Ontario, Canada.
³⁵ Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada.
³⁶ Departments of Surgery and Psychiatry, University of Manitoba, Winnipeg, Manitoba, Canada.
³⁷ Department of Internal Medicine, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada.
³⁸ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
³⁹ CHUM Research Center, Université de Montréal's affiliated hospital research center, Montréal, Québec, Canada.
⁴⁰ Département de médecine de famille et de médecine d'urgence, Université de Montréal, Montréal, Québec, Canada.
⁴¹ Department of Family Medicine, McGill University Faculty of Medicine and Health Sciences, Montreal, Quebec, Canada.
⁴² Public Health and General Practice, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand.
⁴³ Family Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
⁴⁴ Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
⁴⁵ Family Medicine, Providence Health Care, Vancouver, British Columbia, Canada.
⁴⁶ Family Practice, University of British Columbia Faculty of Medicine, Vancouver, British Columbia, Canada.
⁴⁷ Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
⁴⁸ VITAM - Research Centre on Sustainable Health, Sherbrooke, Québec, Canada.
⁴⁹ Département de médecine de famille et de médecine d'urgence, Université Laval, Quebec City, Québec, Canada.
⁵⁰ Laboratoire ARIMED, Saint-Charles-Borromée, Québec, Canada.
⁵¹ Department of Health Research Methods, Evidence and Impact (HEI), Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
⁵² MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada.
⁵³ Program for Health System and Technology Evaluation, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
⁵⁴ Department of Family Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
⁵⁵ Alliance for Healthier Communities, Toronto, Ontario, Canada.
⁵⁶ College of Rehabilitation Sciences, Department of Respiratory Therapy, University of Manitoba, Winnipeg, Manitoba, Canada.
⁵⁷ Department of Medicine, Division of Infectious Diseases, University of Alberta Faculty of Medicine and Dentistry, Edmonton, Alberta, Canada.
⁵⁸ Department of Statistics and Actuarial Science, Simon Fraser University, Burnaby, British Columbia, Canada.
⁵⁹ Manitoba Primary Care Research Network, Winnipeg, Manitoba, Canada.
⁶⁰ Department of Surgery, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁶¹ Manitoba Centre for Health Policy, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁶² Research Institute, Humber River Health, Toronto, Ontario, Canada.
⁶³ South East Toronto Family Health Team, Toronto, Ontario, Canada.
⁶⁴ Joint Centre for Bioethics, University of Toronto, Toronto, Ontario, Canada.
⁶⁵ Evaluative Clinical Sciences Platform, Integrated Community Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁶⁶ Sunnybrook Academic Family Health Team, Toronto, Ontario, Canada.
⁶⁷ Departments of Medicine and of Family Medicine, McGill University, Montreal, Quebec, Canada.
⁶⁸ Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada.
⁶⁹ Centre for Health Services and Policy Research, University of British Columbia, Vancouver, British Columbia, Canada.
⁷⁰ Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario, Canada.
⁷¹ Dr. Gilles Arcand Centre for Health Equity, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.
⁷² Sections of Critical Care and Hematology/Medical Oncology, University of Manitoba, Winnipeg, Manitoba, Canada.
⁷³ Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
⁷⁴ Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
⁷⁵ Faculty of Pharmacy, The University of British Columbia, Vancouver, British Columbia, Canada.
⁷⁶ School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
⁷⁷ Ontario Ministry of Health, Toronto, Ontario, Canada.
⁷⁸ Upstream Lab, MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Ontario, Canada andrew.pinto@utoronto.ca.

PMID: 40754325
PMCID: PMC12320028
DOI: 10.1136/bmjopen-2024-097134

Abstract

Introduction: SARS-CoV-2 is now endemic and expected to remain a health threat, with new variants continuing to emerge and the potential for vaccines to become less effective. While effective vaccines and natural immunity have significantly reduced hospitalisations and the need for critical care, outpatient treatment options remain limited, and real-world evidence on their clinical and cost-effectiveness is lacking. In this paper, we present the design of the Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID). By evaluating multiple treatment options in a pragmatic adaptive platform trial, this study will generate high-quality, generalisable evidence to inform clinical guidelines and healthcare decision-making.

Methods and analysis: CanTreatCOVID is an open-label, individually randomised, multicentre, national adaptive platform trial designed to evaluate the clinical and cost-effectiveness of therapeutics for non-hospitalised SARS-CoV-2 patients across Canada. Eligible participants must present with symptomatic SARS-CoV-2 infection, confirmed by PCR or rapid antigen testing (RAT), within 5 days of symptom onset. The trial targets two groups that are expected to be at higher risk of more severe disease: (1) individuals aged 50 years and older and (2) those aged 18-49 years with one or more comorbidities. CanTreatCOVID uses numerous approaches to recruit participants to the study, including a multifaceted public communication strategy and outreach through primary care, outpatient clinics and emergency departments. Participants are randomised to receive either usual care, including supportive and symptom-based management, or an investigational therapeutic selected by the Canadian COVID-19 Outpatient Therapeutics Committee. The first therapeutic arm evaluates nirmatrelvir/ritonavir (Paxlovid), administered two times per day for 5 days. The second therapeutic arm investigates a combination antioxidant therapy (selenium 300 µg, zinc 40 mg, lycopene 45 mg and vitamin C 1.5 g), administered for 10 days. The primary outcome is all-cause hospitalisation or death within 28 days of randomisation.

Ethics and dissemination: The CanTreatCOVID master protocol and subprotocols have been approved by Health Canada and local research ethics boards in the participating provinces across Canada. The results of the study will be disseminated to policy-makers, presented at conferences and published in peer-reviewed journals to ensure that findings are accessible to the broader scientific and medical communities. This study was approved by the Unity Health Toronto Research Ethics Board (#22-179) and Clinical Trials Ontario (Project ID 4133).

Trial registration number: NCT05614349.

Keywords: COVID-19; Clinical Protocols; Randomized Controlled Trial; SARS-CoV-2 Infection.

PubMed Disclaimer

Conflict of interest statement

Competing interests: One of the coauthors, CCB, is a member of the BMJ Open Editorial Board. However, all opinions, analyses and conclusions presented in the manuscript are solely those of the authors and were made independently of any editorial influence. All other authors have no competing interests to declare.

References

1. World Health Organization WHO coronovirus disease (COVID-19) 2024. https://data.who.int/dashboards/covid19/deaths?n=c Available.
1. Ashton J. COVID-19 and herd immunity. J R Soc Med. 2022;115:76–7. doi: 10.1177/01410768221080824. - DOI - PMC - PubMed
1. Telenti A, Arvin A, Corey L, et al. After the pandemic: perspectives on the future trajectory of COVID-19. Nature New Biol. 2021;596:495–504. doi: 10.1038/s41586-021-03792-w. - DOI - PubMed
1. McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection. Am J Med. 2021;134:16–22. doi: 10.1016/j.amjmed.2020.07.003. - DOI - PMC - PubMed
1. Public Health Agency of Canada COVID-19 treatments. 2022.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Associated data

Actions
- Search in PubMed
- Search in ClinicalTrials.gov

LinkOut - more resources

Full Text Sources
- HighWire
- PubMed Central
Medical
- ClinicalTrials.gov
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings

Affiliations

Canadian Adaptive Platform Trial of Treatments for COVID in Community Settings (CanTreatCOVID): protocol for a randomised controlled adaptive platform trial of treatments for acute SARS-CoV-2 infection in community settings

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Associated data

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous